tiprankstipranks
Trending News
More News >
China NT Pharma Group Co., Ltd. (HK:1011)
:1011
Hong Kong Market
Advertisement

China NT Pharma Group Co., Ltd. (1011) AI Stock Analysis

Compare
1 Followers

Top Page

HK:1011

China NT Pharma Group Co., Ltd.

(1011)

Rating:49Neutral
Price Target:
HK$0.50
▼(-18.03%Downside)
The overall stock score is primarily impacted by significant financial weaknesses, including negative net income and high leverage. While technical indicators suggest potential positive momentum, the poor financial health and unattractive valuation metrics substantially lower the score.

China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)

China NT Pharma Group Co., Ltd. Business Overview & Revenue Model

Company DescriptionChina NT Pharma Group Co., Ltd. (1011) is a Chinese pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceuticals. The company operates in several sectors, including biopharmaceuticals, traditional Chinese medicine, and chemical drugs. Its core products and services include vaccine development, drug manufacturing, and distribution services, focusing on providing accessible healthcare solutions across China.
How the Company Makes MoneyChina NT Pharma Group Co., Ltd. makes money primarily through the sale and distribution of its pharmaceutical products. The company generates revenue by manufacturing and distributing a wide range of drugs, including vaccines, chemical drugs, and traditional Chinese medicines. It leverages a robust distribution network to supply its products to hospitals, pharmacies, and other healthcare facilities. Additionally, NT Pharma collaborates with various international and domestic pharmaceutical companies to enhance its product offerings and expand its market reach. These partnerships, along with its focus on innovation and quality, significantly contribute to the company's earnings.

China NT Pharma Group Co., Ltd. Financial Statement Overview

Summary
China NT Pharma Group Co., Ltd. faces significant financial challenges, including declining revenues, persistent losses, high leverage, and liquidity issues. The company has a negative stockholders' equity and cannot cover net income with operating cash flow, indicating substantial financial instability and insolvency risks.
Income Statement
22
Negative
The company's income statement reflects significant revenue volatility and sustained negative net income over the past years, with a particularly sharp decline in revenue in 2023. The gross profit margin has decreased over time, and the company has struggled to achieve positive EBIT, indicating operational inefficiencies. These factors contribute to a low score.
Balance Sheet
15
Very Negative
The balance sheet shows a concerning financial structure, with negative stockholders' equity indicating insolvency risk. The debt-to-equity ratio cannot be calculated due to negative equity, but the high level of debt relative to assets suggests significant leverage. These elements indicate financial instability, contributing to a low score.
Cash Flow
30
Negative
The cash flow statement reveals erratic cash flow from operations, with a significant decline in free cash flow in 2024. The absence of positive free cash flow growth and the inability to cover net income with operating cash flow highlight liquidity challenges. These factors contribute to a low score.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue37.96M7.37M207.09M226.70M221.73M
Gross Profit5.26M7.37M125.29M145.46M134.90M
EBITDA-8.65M1.33M10.39M-17.78M-43.74M
Net Income-53.36M-143.59M-66.41M-151.33M-191.27M
Balance Sheet
Total Assets334.07M329.12M1.01B955.36M1.30B
Cash, Cash Equivalents and Short-Term Investments9.62M1.52M5.93M9.44M7.69M
Total Debt375.95M344.94M826.45M832.11M851.46M
Total Liabilities733.18M668.69M1.25B1.17B1.27B
Stockholders Equity-399.11M-339.56M-241.66M-211.38M16.28M
Cash Flow
Free Cash Flow-9.24M37.58M31.72M-135.42M2.36M
Operating Cash Flow-9.07M50.48M36.21M-134.78M26.20M
Investing Cash Flow-189.00K-22.14M4.53M257.81M595.60M
Financing Cash Flow12.65M-28.97M-46.68M-124.80M-624.25M

China NT Pharma Group Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.61
Price Trends
50DMA
0.46
Positive
100DMA
0.37
Positive
200DMA
0.33
Positive
Market Momentum
MACD
0.06
Negative
RSI
60.23
Neutral
STOCH
66.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Positive. The current price of 0.61 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.46, and above the 200-day MA of 0.33, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 60.23 is Neutral, neither overbought nor oversold. The STOCH value of 66.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1011.

China NT Pharma Group Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B5.63-7.44%2.87%11.55%-28.15%
60
Neutral
HK$281.90M10.372.72%3.20%-4.17%-1.83%
55
Neutral
HK$365.66M51.590.55%9.23%-66.75%-83.83%
49
Neutral
HK$411.29M
46
Neutral
HK$235.27M-40.39%-43.73%-434.56%
45
Neutral
HK$177.67M-7.93%1.13%38.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1011
China NT Pharma Group Co., Ltd.
0.61
0.33
117.86%
HK:8622
Huakang Biomedical Holdings Company Limited
0.36
0.23
176.92%
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.17
0.09
112.50%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.32
-0.69
-68.32%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
0.14
73.68%

China NT Pharma Group Co., Ltd. Corporate Events

China NT Pharma Delays Circular Dispatch for Acquisition
Jun 30, 2025

China NT Pharma Group Co., Ltd. announced a delay in the dispatch of a circular related to its acquisition of 100% of the issued shares in certain target companies. The circular, which includes details of the Sale and Purchase Agreement and other required information, was initially expected to be sent to shareholders by June 30, 2025, but will now be postponed to on or before October 31, 2025. This delay may impact the timeline for the acquisition process and could have implications for stakeholders awaiting further details.

China NT Pharma Group Successfully Concludes AGM with All Resolutions Passed
Jun 30, 2025

China NT Pharma Group Co., Ltd. announced that all resolutions proposed at their Annual General Meeting (AGM) held on June 30, 2025, were passed by shareholders. The resolutions included the adoption of financial statements, re-election of directors, appointment of auditors, and granting of mandates related to share issuance and repurchase. This successful AGM reflects strong shareholder support and positions the company for continued operational stability and strategic growth.

China NT Pharma Group Announces Board Composition and Committee Roles
Jun 30, 2025

China NT Pharma Group Co., Ltd. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. The announcement also details the membership of the board committees, which is crucial for stakeholders to understand the governance structure and decision-making processes within the company.

China NT Pharma Group Announces Board Committee Changes
Jun 30, 2025

China NT Pharma Group Co., Ltd. has announced changes to its Board Committee, appointing Dr. Zhao Yubiao as Chairman of the Nomination Committee and Ms. Ng Anna Ching Mei as a member, while Mr. Ng Tit has stepped down as Chairman. These changes are effective immediately following the Board’s approval. This restructuring of the Nomination Committee may impact the company’s governance and strategic direction, potentially influencing its decision-making processes and stakeholder engagement.

China NT Pharma Group Updates Nomination Committee Terms
Jun 30, 2025

China NT Pharma Group Co., Ltd. has revised and adopted the terms of reference for its Nomination Committee, which is responsible for overseeing the structure and composition of the Board of Directors. The Nomination Committee will consist of at least two independent non-executive directors and will focus on board diversity, succession planning, and the assessment of director independence. This move aims to enhance corporate governance and align the board’s composition with the company’s strategic goals.

China NT Pharma Announces Leadership Change with New CEO Appointment
May 19, 2025

China NT Pharma Group Co., Ltd. has announced a change in its executive leadership with Mr. Ng Tit stepping down as CEO to focus on strategic development, while remaining as Chairman of the Board. Mr. Zhang Bozhi, an experienced professional in the pharmaceutical industry with a background in sales and management, has been appointed as the new CEO, bringing his expertise to drive the company’s business development and strategic planning.

China NT Pharma Group Announces Potential Acquisition and Disposal Plans
May 12, 2025

China NT Pharma Group Co., Ltd. has announced a potential acquisition and disposal involving its associate, Beijing Kangchen Biotechnology Company Limited. The proposed plan involves splitting the assets of the associate to protect shareholder interests, with the intention of dissolving the associate relationship and allowing independent operations. This move could impact the company’s operations by potentially expanding its asset base and altering its industry positioning, depending on the outcome of negotiations with Konruns Pharmaceutical.

China NT Pharma Achieves Profit Guarantee Milestone with Associate
May 9, 2025

China NT Pharma Group Co., Ltd. announced the successful completion of a profit guarantee related to its associate, Beijing Kangchen Biotechnology Company Limited. The profit guarantee, which was part of a larger acquisition agreement with Beijing Konruns Pharmaceutical Company Limited, required the associate’s Miacalcic business to achieve specific net profit targets from 2021 to 2023. The associate exceeded these targets each year, signaling strong performance and potentially enhancing NT Pharma’s industry positioning and stakeholder confidence.

China NT Pharma Group Announces 2025 AGM and Strategic Resolutions
Apr 30, 2025

China NT Pharma Group Co., Ltd. has announced its Annual General Meeting (AGM) scheduled for June 30, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, re-election of directors, and re-appointment of auditors. The company also seeks shareholder approval to authorize the board to issue additional shares, reflecting its strategic focus on growth and capital management. This move could potentially impact the company’s market positioning and shareholder value.

China NT Pharma Clarifies Financial Figures in Major Acquisition
Apr 29, 2025

China NT Pharma Group Co., Ltd. has issued a clarification regarding its acquisition of 100% of the issued shares in target companies, involving the issuance of consideration shares under a specific mandate. The company corrected financial figures for its PRC Operating Company for the years ending December 2023 and 2024, stating that the figures should be in RMB rather than thousands of RMB. This clarification ensures accurate financial reporting, which is crucial for stakeholders assessing the company’s financial health and strategic acquisitions.

China NT Pharma Group Announces Major Acquisition
Apr 28, 2025

China NT Pharma Group Co., Ltd. has announced a major transaction involving the acquisition of 100% of the issued shares in certain target companies. The acquisition, valued at approximately RMB116.2 million, will be financed through the issuance of consideration shares under a specific mandate, pending shareholder approval. This move is classified as a major transaction under the Hong Kong Stock Exchange’s listing rules, necessitating reporting and shareholder approval. The acquisition aims to expand the company’s operational scope, although its completion is contingent upon meeting certain conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025